Skip to main content
Top
Published in: Current Oncology Reports 5/2020

01-05-2020 | Care | Neuro-oncology (Y Umemura, Section Editor)

Developing Real-world Evidence-Ready Datasets: Time for Clinician Engagement

Authors: James M. Snyder, Jacob A. Pawloski, Laila M. Poisson

Published in: Current Oncology Reports | Issue 5/2020

Login to get access

Abstract

Purpose of Review

Real-world data (RWD) applications in healthcare that support learning health systems and pragmatic clinical trials are gaining momentum, largely due to legislation supporting real-world evidence (RWE) for drug approvals. Clinical notes are thought to be the cornerstone of RWD applications, particularly for conditions with limited effective treatments, extrapolation of treatments from other conditions, or heterogenous disease biology and clinical phenotypes.

Recent Findings

Here, we discuss current issues in applying RWD captured at the point-of-care and provide a framework for clinicians to engage in RWD collection. To achieve clinically meaningful results, RWD must be reliably captured using consistent terminology in the description of our patients.

Summary

RWD complements traditional clinical trials and research by informing the generalizability of results, generating new hypotheses, and creating a large data network for scientific discovery. Effective clinician engagement in the development of RWD applications is necessary for continued progress in the field.
Literature
1.
go back to reference Shanafelt TD, Dyrbye LN, Sinsky C, Hasan O, Satele D, Sloan J, et al. Relationship between clerical burden and characteristics of the electronic environment with physician burnout and professional satisfaction. Mayo Clin Proc. 2016;91:836–48.CrossRef Shanafelt TD, Dyrbye LN, Sinsky C, Hasan O, Satele D, Sloan J, et al. Relationship between clerical burden and characteristics of the electronic environment with physician burnout and professional satisfaction. Mayo Clin Proc. 2016;91:836–48.CrossRef
4.
go back to reference Murthy VH, Krumholz HM, Gross CP. Participation in cancer clinical trials: race-, sex-, and age-based disparities. JAMA. 2004;291:2720–6.CrossRef Murthy VH, Krumholz HM, Gross CP. Participation in cancer clinical trials: race-, sex-, and age-based disparities. JAMA. 2004;291:2720–6.CrossRef
5.
go back to reference Sateren WB, Trimble EL, Abrams J, Brawley O, Breen N, Ford L, et al. How sociodemographics, presence of oncology specialists, and hospital cancer programs affect accrual to cancer treatment trials. J Clin Oncol. 2002;20:2109–17.CrossRef Sateren WB, Trimble EL, Abrams J, Brawley O, Breen N, Ford L, et al. How sociodemographics, presence of oncology specialists, and hospital cancer programs affect accrual to cancer treatment trials. J Clin Oncol. 2002;20:2109–17.CrossRef
6.
go back to reference Unger JM, Gralow JR, Albain KS, Ramsey SD, Hershman DL. Patient income level and cancer clinical trial participation in a prospective survey study. JAMA Oncol. 2016;2:137–9.CrossRef Unger JM, Gralow JR, Albain KS, Ramsey SD, Hershman DL. Patient income level and cancer clinical trial participation in a prospective survey study. JAMA Oncol. 2016;2:137–9.CrossRef
7.
go back to reference Unger JM, Cook E, Tai E, Bleyer A. Role of clinical trial participation in cancer research: barriers, evidence, and strategies. Am Soc Clin Oncol Educ Book Am Soc Clin Oncol Meet. 2016;35:185–98.CrossRef Unger JM, Cook E, Tai E, Bleyer A. Role of clinical trial participation in cancer research: barriers, evidence, and strategies. Am Soc Clin Oncol Educ Book Am Soc Clin Oncol Meet. 2016;35:185–98.CrossRef
8.
go back to reference •• Lee EQ, Chukwueke UN, Hervey-Jumper SL, de Groot JF, Leone JP, Armstrong TS, et al. Barriers to accrual and enrollment in brain tumor trials. Neuro-Oncol. 2019;21:1100–17. Lee et al. provide a thorough discussion of barriers to clinical trial participation in neuro-oncology and offer possible solutions. With such poor outcomes for malignant glioma, every effort should be made to improve access to clinical trials--and this article provides a path to address this gap. •• Lee EQ, Chukwueke UN, Hervey-Jumper SL, de Groot JF, Leone JP, Armstrong TS, et al. Barriers to accrual and enrollment in brain tumor trials. Neuro-Oncol. 2019;21:1100–17. Lee et al. provide a thorough discussion of barriers to clinical trial participation in neuro-oncology and offer possible solutions. With such poor outcomes for malignant glioma, every effort should be made to improve access to clinical trials--and this article provides a path to address this gap.
9.
go back to reference Sertkaya A, Wong H-H, Jessup A, Beleche T. Key cost drivers of pharmaceutical clinical trials in the United States. Clin Trials Lond Engl. 2016;13:117–26.CrossRef Sertkaya A, Wong H-H, Jessup A, Beleche T. Key cost drivers of pharmaceutical clinical trials in the United States. Clin Trials Lond Engl. 2016;13:117–26.CrossRef
10.
go back to reference Vanderbeek AM, Rahman R, Fell G, Ventz S, Chen T, Redd R, et al. The clinical trials landscape for glioblastoma: is it adequate to develop new treatments? Neuro-Oncol. 2018;20:1034–43.CrossRef Vanderbeek AM, Rahman R, Fell G, Ventz S, Chen T, Redd R, et al. The clinical trials landscape for glioblastoma: is it adequate to develop new treatments? Neuro-Oncol. 2018;20:1034–43.CrossRef
11.
go back to reference Kesselheim AS, Avorn J. New “21st Century Cures” legislation: speed and ease vs science. JAMA. 2017;317:581–2.CrossRef Kesselheim AS, Avorn J. New “21st Century Cures” legislation: speed and ease vs science. JAMA. 2017;317:581–2.CrossRef
12.
go back to reference Asher AL, McCormick PC, Selden NR, Ghogawala Z, McGirt MJ. The National Neurosurgery Quality and Outcomes Database and NeuroPoint Alliance: rationale, development, and implementation. Neurosurg Focus. 2013;34:E2.CrossRef Asher AL, McCormick PC, Selden NR, Ghogawala Z, McGirt MJ. The National Neurosurgery Quality and Outcomes Database and NeuroPoint Alliance: rationale, development, and implementation. Neurosurg Focus. 2013;34:E2.CrossRef
13.
go back to reference Collins FS, Hudson KL, Briggs JP, Lauer MS. PCORnet: turning a dream into reality. J Am Med Inform Assoc. 2014;21:576–7.CrossRef Collins FS, Hudson KL, Briggs JP, Lauer MS. PCORnet: turning a dream into reality. J Am Med Inform Assoc. 2014;21:576–7.CrossRef
16.
17.
go back to reference Abernethy AP, Etheredge LM, Ganz PA, Wallace P, German RR, Neti C, et al. Rapid-learning system for cancer care. J Clin Oncol. 2010;28:4268–74.CrossRef Abernethy AP, Etheredge LM, Ganz PA, Wallace P, German RR, Neti C, et al. Rapid-learning system for cancer care. J Clin Oncol. 2010;28:4268–74.CrossRef
18.
go back to reference Sledge GW, Hudis CA, Swain SM, Yu PM, Mann JT, Hauser RS, et al. ASCO’s approach to a learning health care system in oncology. J Oncol Pract. 2013;9:145–8.CrossRef Sledge GW, Hudis CA, Swain SM, Yu PM, Mann JT, Hauser RS, et al. ASCO’s approach to a learning health care system in oncology. J Oncol Pract. 2013;9:145–8.CrossRef
19.
go back to reference Smith MD, Institute of Medicine (U.S.), editors. Best care at lower cost: the path to continuously learning health care in America. Washington, D.C: National Academies Press; 2013. Smith MD, Institute of Medicine (U.S.), editors. Best care at lower cost: the path to continuously learning health care in America. Washington, D.C: National Academies Press; 2013.
22.
go back to reference National Research Council (US) Committee on a framework for developing a new taxonomy of disease. Toward precision medicine: building a knowledge network for biomedical research and a new taxonomy of disease [Internet]. Washington (DC): National Academies Press (US); 2011. [cited 2018 Jul 27]. Available from: http://www.ncbi.nlm.nih.gov/books/NBK91503/. National Research Council (US) Committee on a framework for developing a new taxonomy of disease. Toward precision medicine: building a knowledge network for biomedical research and a new taxonomy of disease [Internet]. Washington (DC): National Academies Press (US); 2011. [cited 2018 Jul 27]. Available from: http://​www.​ncbi.​nlm.​nih.​gov/​books/​NBK91503/​.
23.
go back to reference Louis DN, Perry A, Reifenberger G, von Deimling A, Figarella-Branger D, Cavenee WK, et al. The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary. Acta Neuropathol (Berl). 2016;131:803–20.CrossRef Louis DN, Perry A, Reifenberger G, von Deimling A, Figarella-Branger D, Cavenee WK, et al. The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary. Acta Neuropathol (Berl). 2016;131:803–20.CrossRef
24.
go back to reference Petrone J. Roche pays $1.9 billion for Flatiron’s army of electronic health record curators. Nat Biotechnol. 2018;36:289–90.CrossRef Petrone J. Roche pays $1.9 billion for Flatiron’s army of electronic health record curators. Nat Biotechnol. 2018;36:289–90.CrossRef
25.
go back to reference Grinnon ST, Miller K, Marler JR, Lu Y, Stout A, Odenkirchen J, et al. National Institute of Neurological Disorders and Stroke Common Data Element Project – approach and methods. Clin Trials J Soc Clin Trials. 2012;9:322–9.CrossRef Grinnon ST, Miller K, Marler JR, Lu Y, Stout A, Odenkirchen J, et al. National Institute of Neurological Disorders and Stroke Common Data Element Project – approach and methods. Clin Trials J Soc Clin Trials. 2012;9:322–9.CrossRef
27.
go back to reference Gaddale JR. Clinical data acquisition standards harmonization importance and benefits in clinical data management. Perspect Clin Res. 2015;6:179–83.CrossRef Gaddale JR. Clinical data acquisition standards harmonization importance and benefits in clinical data management. Perspect Clin Res. 2015;6:179–83.CrossRef
28.
go back to reference Snyder J, Wells M, Poisson L, Kalkanis S, Noushmehr H, Robin A. INNV-15. Clinical data that matters: a distillation of neuro-oncology clinical trial inclusion criteria using machine learning. Neuro-Oncol. 2019;21:vi133.CrossRef Snyder J, Wells M, Poisson L, Kalkanis S, Noushmehr H, Robin A. INNV-15. Clinical data that matters: a distillation of neuro-oncology clinical trial inclusion criteria using machine learning. Neuro-Oncol. 2019;21:vi133.CrossRef
29.
go back to reference Reardon DA, Galanis E, DeGroot JF, Cloughesy TF, Wefel JS, Lamborn KR, et al. Clinical trial end points for high-grade glioma: the evolving landscape. Neuro-Oncol. 2011;13:353–61.CrossRef Reardon DA, Galanis E, DeGroot JF, Cloughesy TF, Wefel JS, Lamborn KR, et al. Clinical trial end points for high-grade glioma: the evolving landscape. Neuro-Oncol. 2011;13:353–61.CrossRef
30.
go back to reference Wen PY, Chang SM, Van den Bent MJ, Vogelbaum MA, Macdonald DR, Lee EQ. Response assessment in neuro-oncology clinical trials. J Clin Oncol Off J Am Soc Clin Oncol. 2017;35:2439–49.CrossRef Wen PY, Chang SM, Van den Bent MJ, Vogelbaum MA, Macdonald DR, Lee EQ. Response assessment in neuro-oncology clinical trials. J Clin Oncol Off J Am Soc Clin Oncol. 2017;35:2439–49.CrossRef
31.
go back to reference Frank L, Basch E, Selby JV. The PCORI perspective on patient-centered outcomes research. JAMA. 2014;312:1513–4.CrossRef Frank L, Basch E, Selby JV. The PCORI perspective on patient-centered outcomes research. JAMA. 2014;312:1513–4.CrossRef
32.
go back to reference Chang K, Beers AL, Bai HX, Brown JM, Ly KI, Li X, et al. Automatic assessment of glioma burden: a deep learning algorithm for fully automated volumetric and bidimensional measurement. Neuro-Oncol. 2019;21:1412–22.CrossRef Chang K, Beers AL, Bai HX, Brown JM, Ly KI, Li X, et al. Automatic assessment of glioma burden: a deep learning algorithm for fully automated volumetric and bidimensional measurement. Neuro-Oncol. 2019;21:1412–22.CrossRef
33.
go back to reference Nayak L, DeAngelis LM, Brandes AA, Peereboom DM, Galanis E, Lin NU, et al. The Neurologic Assessment in Neuro-oncology (NANO) scale: a tool to assess neurologic function for integration into the Response Assessment in Neuro-Oncology (RANO) criteria. Neuro-Oncol. 2017;19:625–35.CrossRef Nayak L, DeAngelis LM, Brandes AA, Peereboom DM, Galanis E, Lin NU, et al. The Neurologic Assessment in Neuro-oncology (NANO) scale: a tool to assess neurologic function for integration into the Response Assessment in Neuro-Oncology (RANO) criteria. Neuro-Oncol. 2017;19:625–35.CrossRef
34.
go back to reference Nabors LB, Horbinski C, Robins I. NCCN Guidelines Index Table of Contents Discussion 2019;163. Nabors LB, Horbinski C, Robins I. NCCN Guidelines Index Table of Contents Discussion 2019;163.
35.
go back to reference Dirven L, Armstrong TS, Blakeley JO, Brown PD, Grant R, Jalali R, et al. Working plan for the use of patient-reported outcome measures in adults with brain tumours: a Response Assessment in NEURO-Oncology (RANO) initiative. Lancet Oncol. 2018;19:e173–80.CrossRef Dirven L, Armstrong TS, Blakeley JO, Brown PD, Grant R, Jalali R, et al. Working plan for the use of patient-reported outcome measures in adults with brain tumours: a Response Assessment in NEURO-Oncology (RANO) initiative. Lancet Oncol. 2018;19:e173–80.CrossRef
37.
go back to reference • Ching T, Himmelstein DS, Beaulieu-Jones BK, Kalinin AA, Do BT, Way GP, et al. Opportunities and obstacles for deep learning in biology and medicine. J R Soc Interface. 2018;15:20170387. Deep learning applications in healthcare are rapidly developing and promise to drastically alter medical practice. Ching et al. provide a stunning overview of deep learning applications in healthcare with relevance to clinically integrated RWD capture and analysis. CrossRef • Ching T, Himmelstein DS, Beaulieu-Jones BK, Kalinin AA, Do BT, Way GP, et al. Opportunities and obstacles for deep learning in biology and medicine. J R Soc Interface. 2018;15:20170387. Deep learning applications in healthcare are rapidly developing and promise to drastically alter medical practice. Ching et al. provide a stunning overview of deep learning applications in healthcare with relevance to clinically integrated RWD capture and analysis. CrossRef
39.
go back to reference •• Grossman RL, Heath AP, Ferretti V, Varmus HE, Lowy DR, Kibbe WA, et al. Toward a shared vision for cancer genomic data. N Engl J Med 2016;375:1109–1112. This manuscript eloquently illustrates the mission of the Genomic Data Commons and outlines a plan for a truly collaborative and inclusive research environment to address multidimensional omics data and leverage available resources. CrossRef •• Grossman RL, Heath AP, Ferretti V, Varmus HE, Lowy DR, Kibbe WA, et al. Toward a shared vision for cancer genomic data. N Engl J Med 2016;375:1109–1112. This manuscript eloquently illustrates the mission of the Genomic Data Commons and outlines a plan for a truly collaborative and inclusive research environment to address multidimensional omics data and leverage available resources. CrossRef
41.
42.
go back to reference Thorpe KE, Zwarenstein M, Oxman AD, Treweek S, Furberg CD, Altman DG, et al. A pragmatic–explanatory continuum indicator summary (PRECIS): a tool to help trial designers. J Clin Epidemiol. 2009;62:464–75.CrossRef Thorpe KE, Zwarenstein M, Oxman AD, Treweek S, Furberg CD, Altman DG, et al. A pragmatic–explanatory continuum indicator summary (PRECIS): a tool to help trial designers. J Clin Epidemiol. 2009;62:464–75.CrossRef
Metadata
Title
Developing Real-world Evidence-Ready Datasets: Time for Clinician Engagement
Authors
James M. Snyder
Jacob A. Pawloski
Laila M. Poisson
Publication date
01-05-2020
Publisher
Springer US
Keyword
Care
Published in
Current Oncology Reports / Issue 5/2020
Print ISSN: 1523-3790
Electronic ISSN: 1534-6269
DOI
https://doi.org/10.1007/s11912-020-00904-z

Other articles of this Issue 5/2020

Current Oncology Reports 5/2020 Go to the issue

Lung Cancer (H Borghaei, Section Editor)

New Targets in Lung Cancer (Excluding EGFR, ALK, ROS1)

Lymphomas (MR Smith, Section Editor)

Hairy Cell Leukaemia

Gastrointestinal Cancers (J Meyer, Section Editor)

Updates on Imaging of Liver Tumors

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine